DLL3 can be targeted by the antibody-drug conjugate SC16LD6.5 (Rovalpituzumab Tesirine); treatment with this antibody resulted in complete and durable response in DLL3+ prostate cancer xenograft models [679]. This evidence concerns the gene DLL3 and prostate carcinoma.